Back to Blog

Field Safety Testing of Canine Osteosarcoma Vaccine, Live Listeria Vector

Aug 03, 2018


The University of Pennsylvania’s Canine osteosarcoma vaccine with a live listeria vector is now being offered as part of an exciting clinical trial. This is a partially-funded trial once the pet is screened and is accepted into the trial. Dogs will receive one vaccine every 3-4 weeks for 3 cycles. Dogs will be required to stay in our hospital to be monitored for 6 hours after each vaccination.

  • Client owned dog >1 year of age
  • Body weight ≥ 2kg
  • Histopathological diagnosis of osteosarcoma
  • Undergone amputation of the affected limb followed by 4-6 doses of carboplatin (given every 2-4 weeks)
  • Free of pulmonary metastatic disease, as evidenced by radiographs at the time of screening
  • Performance score of 0 or 1
  • Clinically relevant abnormalities on CBC/CS/UA
  • Evidence of pulmonary metastases on 3-view thoracic radiographs
  • Prior immunotherapy
  • Any uncontrolled medical condition (including other concurrent malignancy) that may be disruptive to theintent or objectives of the study
  • Dog is pregnant or is likely to become pregnant
  • Dog is participating in another study
  • Dog may not be available for the entire study duration

Partially-Funded Trial


This will be confirmed by reviewing the dog’s medical history, performing a physical exam, taking thoracic radiographs, and submitting routine blood and urine tests. All dogs enrolled in the safety study will be treated with COV-LLV.